Curi RMB Capital LLC Grows Stock Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

Curi RMB Capital LLC raised its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 0.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 421,933 shares of the medical equipment provider’s stock after buying an additional 2,283 shares during the period. Curi RMB Capital LLC owned about 0.91% of BioLife Solutions worth $10,565,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the business. 1620 Investment Advisors Inc. purchased a new position in shares of BioLife Solutions in the 2nd quarter valued at $35,000. Isthmus Partners LLC grew its stake in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 42,265 shares during the last quarter. GAMMA Investing LLC grew its position in BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of BioLife Solutions during the second quarter worth about $122,000. Finally, Arizona State Retirement System purchased a new stake in BioLife Solutions in the 2nd quarter valued at approximately $217,000. 93.24% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other BioLife Solutions news, CRO Garrie Richardson sold 3,070 shares of BioLife Solutions stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now owns 114,773 shares in the company, valued at $2,883,097.76. The trade was a 2.61 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total transaction of $239,000.00. Following the transaction, the executive vice president now owns 317,716 shares in the company, valued at approximately $7,593,412.40. The trade was a 3.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 27,471 shares of company stock valued at $656,330 over the last 90 days. Insiders own 2.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. TD Cowen lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday. HC Wainwright began coverage on shares of BioLife Solutions in a research report on Monday, September 30th. They set a “buy” rating and a $29.00 price target for the company. Craig Hallum raised their price objective on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Northland Securities boosted their target price on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and an average price target of $27.83.

BioLife Solutions Trading Down 10.2 %

BioLife Solutions stock opened at $21.65 on Friday. The stock has a market cap of $998.93 million, a PE ratio of -20.42 and a beta of 1.88. The company has a current ratio of 2.86, a quick ratio of 1.81 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average price of $24.05 and a 200 day moving average price of $22.72. BioLife Solutions, Inc. has a 52 week low of $11.40 and a 52 week high of $28.88.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.